Clinical trial
An i3+3 Phase I Hypofractionation Trial for Multiple Myeloma
NCT06270888 is registered in ClinicalTrials.gov with University of Chicago as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- An i3+3 Phase I Hypofractionation Trial for Multiple Myeloma
- Lead sponsor
- University of Chicago
- Phase
- Phase 1
- Overall status
- Recruiting
- Start date
- September 8, 2025
- Completion date
- May 1, 2028
- Enrollment
- 30 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.